Modified Bethesda system informing cytopathologic adequacy improves malignancy risk stratification in nodules considered benign or atypia (follicular lesion) of undetermined significance

You-Bin Lee1,2, Ji-Ye Kim3, Haeyon Cho3, Soo Yeon Hahn4, Jung Hee Shin4, Seung-Eun Lee2, Ji Eun Jun5, Sun Wook Kim2, Jae Hoon Chung3, Tae Hyuk Kim2 & Young Lyun Oh3

We modified the nondiagnostic/unsatisfactory category of the Bethesda system for reporting thyroid cytopathology to inform cytopathologic adequacy to better stratify the malignancy risk. Malignancy rates from 1,450 cytopathologic specimens not satisfying adequacy criteria from April 2011 to March 2016 were calculated based on sub-classification of the nondiagnostic/unsatisfactory category and sonographic patterns using matched surgical pathology. Rates were compared with those of 1,446 corresponding adequate specimens from July to December 2013. Upon resection, 63.2% of nondiagnostic, 36.7% of unsatisfactory + benign, 72.5% of unsatisfactory + atypia (follicular lesion) of undetermined significance, 98.1% of unsatisfactory + suspicious for malignancy, and 100.0% of unsatisfactory + malignant cases were confirmed to be malignant on surgical pathology. In nodules with inadequate specimens, those with high suspicion sonographic patterns had a malignancy rate (93.2%) higher than the others (45.5%) (p < 0.001). Nodules with unsatisfactory + benign specimens had a higher malignancy rate (36.7%) than satisfactory benign specimens (14.3%) (p = 0.020). For atypia (follicular lesion) of undetermined significance, the malignancy rate of inadequate specimens (72.5%) was higher than that of adequate specimens (51.3%) (p = 0.027). Sparse cellular samples with a few groups of benign follicular cells should not represent a benign lesion. There might be value in qualifying atypia (follicular lesion) of undetermined significance cases less than optimal.

Thyroid fine needle aspiration (FNA) is the standard tool for investigating and triaging thyroid nodules for surgery or clinical observation1–3. The Bethesda system for reporting thyroid cytopathology (TBSRTC) was set up by the 2007 National Cancer Institute meeting, which standardized the reporting of thyroid cytopathology1,4. Six diagnostic categories in this system are linked to certain ranges of malignancy risk and clinical management guidelines1,4,5. However, the nondiagnostic/unsatisfactory (ND/UNS) category among the six tiers of TBSRTC is a major limitation of thyroid FNA2.

1Division of Endocrinology and Metabolism, Department of Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. 2Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 4Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 5Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea. Correspondence and requests for materials should be addressed to T.H.K. (email: taehyukmd.kim@samsung.com) or Y.L.O. (email: bijou@skku.edu)
Although TBSRTC suggests that ND/UNS results should be ideally limited to less than 10% of all thyroid FNA specimens\(^5\), the actual percentage ranged up to 23.6% according to a meta-analysis\(^1\). Factors that affect the rates of inadequate FNA include the experience of aspirators and cytopathologists, onsite adequacy assessment, and adequacy criteria\(^2\). However, inadequacy rates also depend on the characteristics of the nodule itself, such as size or radiological features\(^4\). Regarding the high percentage of ND/UNS cases, Renshaw pointed out that published studies were performed in academic centers or large reference centers where technically challenging cases are sent for aspiration\(^5,7\). In these nodules in which aspirations are technically difficult, it may be challenging to obtain an adequate sample even with repeat FNAs. Moreover, nodules with inadequate specimens have been managed in various ways in previous series\(^8\). Therefore, malignancy risk of inadequate FNAs, which are obtained in a relatively large proportion of patients, should be predicted using information like cytopathologic features and sonographic findings of the thyroid nodules. It is essential to establish proper and consistent guidelines for the management of thyroid nodules with inadequate aspirates.

In our center, we modified the ND/UNS category to suit the needs of clinicians, and we commented on the sample quality (less than optimal) with five TBSRTC categories (from 'unsatisfactory + benign' to 'unsatisfactory + malignant'). We expected that these modifications would enhance quality control of aspirators by indicating the adequacy of specimens. We also tried to reduce the high non-diagnosable rates that occur frequently at tertiary referral centers and result in difficulties in clinical decisions. The main objective of this study was to determine the risk of malignancy (ROM) in thyroid nodules in the ND/UNS category. These samples were re-categorized according to our modified classification system, and their ROM was compared with that of corresponding adequate specimens. We also investigated the sonographic patterns of these nodules with inadequate FNAs, as this information is of clinical relevance for determining ROM\(^9\).

Results

Characteristics of the study population and included nodules. During the five-year study period, 1,450 thyroid aspirations from 1,423 patients were included (Supplementary Table S1). The mean age of the study population was 52.5 ± 11.9 years. Of the 1,423 individuals, 1,058 (74.3%) were females, and 365 (25.7%) were males. The median nodule size was 1.20 cm. Of 1,450 thyroid nodules, 213 (14.7%) were surgically resected.

Malignancy rates in nodules with ND/UNS cytopathology. The maximum and minimum malignancy rates according to the six ND/UNS categories and sonographic patterns are presented in Table 1. Of the 213 excised nodules, 63.2% (12 of 19) of ND FNAs, 36.7% (22 of 60) of UNS + benign aspirates, 72.5% (50 of 69) of UNS + atypia (or follicular lesion) of undetermined significance (AUS/FLUS), 98.1% (53 of 54) of UNS + suspicious for malignancy (SM), and 100.0% (9 of 9) of UNS + malignant cytology cases were malignant on surgical pathology. However, the UNS + follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN) category did not have enough cases to assess the ROM. Among the 146 malignant nodules confirmed by surgical pathology, 136 (93.2%) cases were papillary thyroid carcinomas, 8 (5.5%) cases were follicular thyroid carcinomas, and the rest two nodules included poorly differentiated carcinoma and medullary thyroid carcinoma, respectively (Supplementary Table S2).

High suspicion sonographic patterns were associated with increased ROM in ND/UNS nodules. The maximum malignancy rate of ND/UNS nodules with a high suspicion ultrasound (US) pattern was 93.2%, while that of ND/UNS nodules without a high suspicion pattern was 45.5% (p for difference < 0.001). The difference in proportion was 47.7% [95% confidence interval (CI) 35.8–58.0%]. Moreover, the minimum malignancy rate of sonographically high suspicion ND/UNS nodules (37.5%) was 33.3% higher than that of ND/UNS nodules without a high suspicion US pattern (4.2%) (p for difference < 0.001). The 95% CI for the difference in proportion was 27.2–39.6%.

Comparison of malignancy rates and diagnostic values in inadequate and adequate FNAs. Table 2 presents malignancy rates by TBSRTC category of the 1,446 specimens that met the adequacy criteria. They were compared to the malignancy rates of 1,219 inadequate specimens (Table 3). In AUS/FLUS, the maximum and minimum malignancy rates of inadequate FNAs were significantly higher than those of adequate specimens (p for difference 0.027 and 0.007, respectively). When the UNS + AUS/FLUS samples were compared with adequate AUS/FLUS specimens, the difference in maximum malignancy rate was 21.2% (95% CI 0.9–40.5%), while the difference in minimum malignancy rate was 11.1% (95% CI 2.8–19.0%). Conversely, the difference in proportion was 47.7% [95% confidence interval (CI) 35.8–58.0%]. Moreover, the minimum malignancy rate of sonographically high suspicion ND/UNS nodules (37.5%) was 33.3% higher than that of ND/UNS nodules without a high suspicion US pattern (4.2%) (p for difference < 0.001). The 95% CI for the difference in proportion was 27.2–39.6%.

Malignancy rates in nodules with ND cytopathology according to its characteristics. Specimens in the ND category were sub-classified by the factors that led to ND categorization (Table 5). Insufficient cellularity accounted for most cases. Malignancy rates were individually calculated according to the ND characteristics (Table 5). Although there were not enough cases to ensure adequate evaluation, except in the ‘insufficient cellularity’ group, specimens in the ‘mainly calcified material only’ group showed a relatively high malignancy rate of minimum 16.7%.
Discussion
We screened 16,321 thyroid FNAs that had been assessed for adequacy and seen over a five-year period at a tertiary referral center. We identified 1,450 thyroid FNAs that did not meet adequacy criteria and compared their ROMs with those of a historical control group of adequate FNAs. In reporting cytopathologic inadequacy along with TBSRTC category, we caution clinicians of the specimens' limitations while providing the best information possible from the given specimen to enable further assessment with the help of complementary modalities, such as ultrasonographic findings. Importantly, this study demonstrated that differentiating inadequate FNAs does result in significantly different malignancy predictions, specifically in the benign and AUS/FLUS categories. These results imply that insufficient specimen quantities may under-represent rather than over-represent atypia.

Table 1. Malignancy rates for thyroid nodules that did not meet adequacy criteria and subsequent resection according to sonographic patterns and six nondiagnostic or unsatisfactory subcategories modified from the Bethesda System for Reporting Thyroid Cytopathology from April 2011 to March 2016. Abbreviations: FNA: fine-needle aspiration; ATA: American Thyroid Association; AUS/FLUS: atypia (or follicular lesion) of undetermined significance; FN/SFN: follicular neoplasm or suspicious for a follicular neoplasm; NA: not applicable. *Percentage of cases calculated from total number of resected cases in each category (maximum malignancy rate). †Percentage of cases calculated from total number of fine-needle aspirations in each category (minimum malignancy rate).

| FNA cytopathology          | ATA nodule sonographic patterns | All FNAs (Number) | Surgically resected nodules (Number) | Malignant nodules confirmed by surgery (Number) | Malignancy rate |
|----------------------------|---------------------------------|-------------------|--------------------------------------|-----------------------------------------------|----------------|
|                            |                                 |                   |                                      |                                               | % maximum¹      |
|                            |                                 |                   |                                      |                                               | % minimum¹      |
| Nondiagnostic              | High suspicion                  | 30                | 9                                    | 8                                             | 88.9%           |
|                            | Others                          | 201               | 10                                   | 4                                             | 40.0%           |
|                            | Overall                         | 231               | 19                                   | 12                                            | 63.2%           |
|                            |                                  |                   |                                      |                                               | 5.2%            |
| Unsatisfactory + Benign    | High suspicion                  | 76                | 10                                   | 7                                             | 70.0%           |
|                            | Others                          | 836               | 50                                   | 15                                            | 30.0%           |
|                            | Overall                         | 912               | 60                                   | 22                                            | 36.7%           |
|                            |                                  |                   |                                      |                                               | 2.4%            |
| Unsatisfactory + AUS/FLUS  | High suspicion                  | 79                | 35                                   | 32                                            | 91.4%           |
|                            | Others                          | 132               | 34                                   | 18                                            | 52.9%           |
|                            | Overall                         | 211               | 69                                   | 50                                            | 72.5%           |
|                            |                                  |                   |                                      |                                               | 23.7%           |
| Unsatisfactory + FN/SFN    | High suspicion                  | 0                 | 0                                    | 0                                             | NA              |
|                            | Others                          | 3                 | 2                                    | 0                                             | 0.0%            |
|                            | Overall                         | 3                 | 2                                    | 0                                             | 0.0%            |
|                            |                                  |                   |                                      |                                               | 0.0%            |
| Unsatisfactory + Suspicious for malignancy | High suspicion | 54                | 41                                   | 41                                            | 100.0%          |
|                            | Others                          | 21                | 13                                   | 12                                            | 92.3%           |
|                            | Overall                         | 75                | 54                                   | 53                                            | 98.1%           |
|                            |                                  |                   |                                      |                                               | 70.7%           |
| Unsatisfactory + Malignant | High suspicion                  | 17                | 8                                    | 8                                             | 100.0%          |
|                            | Others                          | 1                 | 1                                    | 1                                             | 100.0%          |
|                            | Overall                         | 18                | 9                                    | 9                                             | 100.0%          |
|                            |                                  |                   |                                      |                                               | 50.0%           |
| Total                      |                                 | 256               | 103                                  | 96                                            | 93.2%           |
|                            | Others                          | 1194              | 110                                  | 50                                            | 45.5%           |
|                            | Overall                         | 1450              | 213                                  | 146                                           | 68.5%           |
|                            |                                  |                   |                                      |                                               | 10.1%           |

Table 2. Malignancy rates for thyroid nodules that met adequacy criteria and subsequent resection according to cytopathologic categories based on the Bethesda System for Reporting Thyroid Cytopathology from July to December 2013. Abbreviations: FNA: fine-needle aspiration; AUS/FLUS: atypia (or follicular lesion) of undetermined significance; FN/SFN: follicular neoplasm or suspicious for a follicular neoplasm. *Percentage of cases calculated from total number of resected cases in each category (maximum malignancy rate). †Percentage of cases calculated from total number of fine-needle aspirations in each category (minimum malignancy rate).

| FNA cytopathology          | All FNAs (Number) | Surgically resected nodules (Number) | Malignant nodules confirmed by surgery (Number) | Malignancy rate |
|----------------------------|-------------------|--------------------------------------|-----------------------------------------------|----------------|
|                            |                   |                                      |                                               | % maximum¹      |
|                            |                   |                                      |                                               | % minimum¹      |
| Benign                     | 857               | 35                                   | 5                                             | 14.3%           |
|                            |                   |                                      |                                               | 0.6%            |
| AUS/FLUS                   | 159               | 39                                   | 20                                            | 51.3%           |
|                            |                   |                                      |                                               | 12.6%           |
| FN/SFN                     | 20                | 9                                    | 3                                             | 33.3%           |
|                            |                   |                                      |                                               | 15.0%           |
| Suspicious for malignancy  | 62                | 40                                   | 39                                            | 97.5%           |
|                            |                   |                                      |                                               | 62.9%           |
| Malignant                  | 348               | 222                                  | 222                                           | 100.0%          |
|                            |                   |                                      |                                               | 63.8%           |
| Total                      | 1446              | 345                                  | 289                                           | 83.8%           |
|                            |                   |                                      |                                               | 20.0%           |
Diagnostic accuracy (malignant, suspicious for malignancy, FN/SFN, and benign) ‡ 100/125 (80.0%) 294/306 (96.1%)

PPV for malignant, suspicious for malignancy, and FN/SFN † 62/65 (95.4%) 264/271 (97.4%) 0.387

Specificity (excluding AUS/FLUS) ‡ 38/60 (63.3%) 30/37 (81.1%) 0.128

PPV for malignant, suspicious for malignancy, and FN/SFN§ 62/65 (94.4%) 264/271 (97.4%) 0.387

NPV for benign cytology 38/60 (63.3%) 30/35 (85.7%) 0.020

Diagnostic accuracy (malignant, suspicious for malignancy, FN/SFN, AUS/FLUS and benign) § 150/194 (77.3%) 314/345 (91.0%) < 0.001

Diagnostic accuracy (malignant, suspicious for malignancy, FN/SFN, and benign) § 100/125 (80.0%) 294/306 (96.1%) < 0.001

Table 3. Comparison of malignancy rates for inadequate and adequate fine needle aspirations. Abbreviations: FNA: fine-needle aspiration; AUS/FLUS: atypia (or follicular lesion) of undetermined significance; FN/SFN: follicular neoplasm or suspicious for a follicular neoplasm; NA: not applicable. *Cases were collected from April 2011 to March 2016. †Cases were collected from July to December 2013. §Pearson’s Chi-square test was applied for comparison. ¶Fisher’s exact test was performed for analysis.

Table 4. Comparison of main diagnostic values for inadequate and adequate fine needle aspirations. Abbreviations: FNA: fine-needle aspiration; AUS/FLUS: atypia (or follicular lesion) of undetermined significance; FN/SFN: follicular neoplasm or suspicious for a follicular neoplasm; PPV: positive predictive value; NPV: negative predictive value. †The non-diagnostic category was excluded. ‡AUS/FLUS, FN/SFN, suspicious for malignancy, and malignant nodules with malignant surgical pathology were considered true-positives. ††Cases interpreted as non-diagnostic or AUS/FLUS were excluded. §FN/SFN, suspicious for malignancy, and malignant cases confirmed to be malignant were considered true-positives. *Cases were collected from April 2011 to March 2016. *Cases were collected from July to December 2013.

According to TBSRTC, the presence of any atypia is one exception to the numerical adequacy criteria requirements.4,5. FNAs with atypia are, by definition, considered satisfactory for evaluation.4,5. In contrast, we sub-classified atypia-bearing specimens that did not meet adequacy criteria into UNS + AUS/FLUS, UNS + FN/SFN, UNS + SM, and UNS + malignant categories, and distinguished them from the adequate cases with atypia. In this study, the malignancy rates did not change with satisfaction of adequacy criteria in malignant or SM specimens. Therefore, meeting the adequacy criteria may not be necessary in these categories, as recommended by TBSRTC. However, in the AUS/FLUS category, malignancy rates of inadequate specimens were significantly higher than those of specimens meeting adequacy criteria. This suggests that adequacy of samples may be important to assess the ROM in AUS/FLUS, unlike in the malignant or SM category. Therefore, in AUS/FLUS samples, it may be useful to indicate specimen adequacy in cytopathologic reports. Recently, personalized approaches utilizing all available information including clinical, radiologic, and cytopathologic data, have been recommended to manage AUS/FLUS lesions.4,5. Modifying TBSRTC to state satisfaction of adequacy criteria in AUS/FLUS specimens may provide useful information for individualized assessment. Moreover, AUS/FLUS results in inadequate samples may need to be managed with more prudence because of the substantially higher ROM. In particular, if AUS/FLUS nodules with inadequate specimens are accompanied by high suspicion patterns on sonography, they may need to be referred directly for surgery rather than for repeat FNA since the ROM in this group was at least 40.5% in this study.

Recent studies have suggested that the required number of follicular cells for adequate thyroid FNAs can be lowered without significantly affecting sensitivity6,11 and/or ROM41. However, in one of these reports6, only FNAs examined with ThipPrep were included, and aspirations with conventional smears were not considered. Another study by Renshaw41 was performed with 170 surgically-matched ND/UNS FNAs including only benign appearing follicular cells and those without Hürthle cells or atypia. Malignancy risk and test performances including sensitivity and specificity in these samples were compared by lowering the threshold of adequacy. Therefore, the ROM and diagnostic values were assessed only in ND/UNS specimens with benign appearing follicular cells, and they were not compared with completely adequate samples. In our study, the ROM in FNAs consistent with benign follicular nodules not fulfilling adequacy criteria was compared to that of benign specimens meeting adequacy...
features13,15–17. Recently, there has been an attempt to stratify the malignancy risk of thyroid nodules based on a scoring system that combines FNA cytology and ultrasound patterns12. However, the role of ultrasound in pre-

Table 5. Malignancy rates for thyroid nodules with nondiagnostic fine needle aspirations according to characteristics of nondiagnostic cytopathology from April 2011 to March 2016. Abbreviations: FNA: fine-needle aspiration. 1Percentage of cases calculated from total number of resected cases in each category (maximum malignancy rate). 2Percentage of cases calculated from total number of fine-needle aspirations in each category (minimum malignancy rate). 3One of these cases was also included in the subcategory of insufficient cellularity. 4Nineteen of these cases were also included in the subcategory of insufficient cellularity. 5All six of these cases were also included in the subcategory of insufficient cellularity.

criteria. The malignancy rates were significantly higher in inadequate specimens than in adequate ones. Also, in inadequate samples, the sensitivity was lower and false-negatives were higher compared to adequate specimens. These results suggest that meeting the adequacy criteria may be important to establish a benign FNA and to minimize false-negative results.

Ultrasoundography plays an important role in stratifying the malignancy risk of thyroid nodules12–14. Malignancy risk-stratification systems have been developed to stratify the cancer risk of thyroid nodules based on sonographic features15–17. Recently, there has been an attempt to stratify the malignancy risk of thyroid nodules based on a scoring system that combines FNA cytology and ultrasound patterns12. However, the role of ultrasound in predicting cancer risk in nodules with ND/UNS FNAs only has not been sufficiently explored in previous reports. In this study, we demonstrated that ultrasoundography plays an essential adjunct role in estimating malignancy risk, even in nodules in which FNA results did not meet the adequacy criteria.

In our study, the minimum malignancy rate was 5.2% in ND samples for which classification into a certain category was impossible. However, in ND samples with the subcategory of ‘mainly calcified material only’, the malignancy rate was estimated to be as high as at least 16.7%. Although calcification itself may result in inadequate nodule aspiration1, calcification within a solitary thyroid nodule has been reported to be associated with a high malignancy risk18,19. In a report by Khoo et al.15, 28 (75.7%) of 37 solitary nodules with intra-thyroidal calcification were carcinomas, and they recommended surgical resection in these lesions regardless of FNA results15. In our previous report4, two of three thyroid nodules with ND samples and malignant histology on resection showed calcification on preoperative sonography. Calcified materials in thyroid aspirations may be a useful finding that indicates an increased ROM. Referring to the presence of calcified material in reports of ND cytology may be helpful to estimate the malignancy risk. ND samples with only calcified material may need to be treated carefully to consider the possibility of cancer.

There are some limitations to our study. First, only three cases were classified as UNS + FN/SFN. Thus, the malignancy rate in this category could not be evaluated. Although this may be associated with a relatively lower prevalence of follicular thyroid cancer and a subsequently lower proportion of FN/SFN cases among thyroid FNAs in Korea compared to Western countries4, it may also be altered because FNA is unable to distinguish follicular lesions accurately. Second, because our study was retrospective in design and the results of inadequate specimens were compared with those of adequate FNAs from a previous study, follow-up periods were not unified. Third, data were analyzed per nodule, not per participant, which may have led to an overestimation of our findings. However, when we performed the same analysis after excluding cases where two or more nodules were included from one patient, the results were not altered. Fourth, only 14.7% of thyroid nodules with inadequate FNAs were histologically confirmed by surgical pathology, suggesting that repeated FNA as recommended by TBSTRC or other clinical factors might have affected surgical triaging of these nodules with less than optimal specimens.

Taken together, the study results confirmed several tenets of TBSRTC approach to adequacy: 1) A sample should be considered ND/UNS if it is sparsely cellular, even if there are a few groups of benign follicular cells. 2) A case with any atypia should not be considered ND/UNS. The novel conclusion of our study is that there is likely value in qualifying AUS/FLUS cases that are less than optimal. The results need to be confirmed by other investigators before considering amendments to TBSRTC to inform cytopathologic adequacy.

Methods
Case selection and cytopathologic diagnosis. This study was conducted at a hospital-based tertiary referral center in Korea. In April 2011, our pathology department adopted TBSRTC to report thyroid FNA results according to the six-tier diagnostic scheme, and modified the criteria of the ND/UNS category of the Bethesda system. A total of 16,321 thyroid aspiration cases were retrieved from the medical records of the Pathology Department of the Samsung Medical Center in Seoul, from April 2011 to March 2016. Among these cases, only specimens that did not meet our adequacy criteria were retrospectively collected as follows. We excluded adequate FNAs satisfying numerical requirements (n = 14,836), which included at least six groups of well-visualized follicular cells and a minimum of ten cells per group4,5. According to TBSRTC recommendations, solid nodules
with inflammation in which a specific diagnosis, such as lymphocytic thyroiditis or granulomatous thyroiditis, can be made are classified as benign, and numerical adequacy requirements do not need to be met in such nodules4,5. In our study, such specimens consistent with lymphocytic thyroiditis in the proper clinical context or granulomatous thyroiditis (n = 35) were excluded. We enrolled the remaining 1,450 thyroid aspirations from 1,423 patients and subdivided them as follows: “nondiagnostic (ND)” referred to samples that were completely acellular or extensively obscured with artifacts; "unsatisfactory (UNS) + benign” referred to samples that had some benign follicular cells organized into small macrofollicular fragments with portions of colloid but lacking the recommended quantity of follicular cells for a benign interpretation. The current TBSRTC recommends that whenever follicular cells organized into small macrofollicular fragments with portions of colloid but lacking the recom- or extensively obscured with artifacts; “unsatisfactory (UNS) + benign” referred to samples that had low cellular- or other obscuring features into “UNS + AUS/FLUS”, “UNS + FN/SFN”, “UNS + SM”, and “UNS + malignant”. These cytopathologic diagnoses were routinely made by the Pathology Department, and difficult cases were con- sulted on a single expert thyroid pathologist (YLO).

**Specimen preparation and review of ultrasound images.** Either radiologists or endocrinologists per- formed thyroid FNAs with 22- or 23-gauge needles attached to 10-mL syringes under US guidance. Sonographic examinations were performed using a 5–12 MHz linear array transducer (iU22; Philips Medical Systems, Bothell, WA). For a nodule, an average of 2–4 passes was applied. Direct smears on glass slides were fixed immediately in 95% alcohol for Papanicolaou and hematoxylin and eosin staining.

All US images taken on the same day as FNAs were retrospectively reviewed. Sonographic features of nodules including composition (presence of solid components), echogenicity of the solid portion (marked hypoechoic, mild hypoechoic, isoechoic, hyperechoic, or hyperechoic), orientation (parallel or non-parallel), and presence of microcalcifi- cation, extra-thyroidal extension or rim calcifications with small extrusive soft tissue components were analyzed. On the basis of these features, images of each nodule were interpreted according to recommendations of the 2015 revised American Thyroid Association (ATA) guidelines13 (Supplementary Table S3). Although the ATA guidelines13 suggest categorizing the sonographic patterns of thyroid nodules into five groups (high, intermediate, low, very low suspicion of malignancy, or benign), we applied a binary classification according to whether the US patterns were compatible with high suspicion nodules or not (high suspicion nodules versus others). High suspi- cion nodules were solid hypoechoic nodules or partially cystic nodules containing solid hypoechoic components with a minimum of one suspicious sonographic feature14. Suspicious US features included irregular margins, microcalcifications, non-parallel orientations, rim calcifications with small extrusive soft tissue components, and extra-thyroidal extension15.

**Histological follow-up.** Cases included in the study were followed until February 2017 to determine whether they were surgically resected. FNA reports of resected nodules were matched to surgical pathology spec- imens. Surgical pathology subtypes included papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated thyroid carcinoma, medullary thyroid carcinoma, hyalining trabecular tumor, follicular adenoma, and benign follicular nodules (Supplementary Table S2), and no anaplastic thyroid carcinomas were observed. These categories were based on the World Health Organization (WHO) classification20. Among these subtypes, papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated thyroid carcinoma, and medul- lary thyroid carcinoma were considered as malignant histology. Malignancy rates were calculated according to six ND/UNS categories (ND, UNS + benign, UNS + AUS/FLUS, UNS + FN/SFN, UNS + SM, or UNS + malignant) and by binary classification of sonographic patterns. In the ND category, malignancy rates were also evaluated based on the ND subcategories, which were created according to the scenarios leading to ND result. They con- sisted of insufficient cellularity, cystic fluid only, obscuring blood, drying artifact, and mainly calcified material only.

Malignancy rates were estimated in two ways: maximum malignancy rate and the minimum malignancy rate1,3. The maximum malignancy rate was calculated only for resected nodules, and it was determined by dividing the number of surgically confirmed malignant nodules by the number of nodules chosen to undergo surgery. The minimum malignancy rate was estimated by dividing the number of surgically confirmed malignant nodules by the total number of nodules aspirated, whether or not they were resected. Noninvasive follicular thyroid neo- plasm with papillary-like nuclear features (NIFTP) was not considered a malignancy22.

**Comparison with adequate aspirates.** In our previous study1, FNAs for thyroid nodules performed from July to December 2013 were followed until February 2015 and retrospectively analyzed. The malignancy rate in each TBSRTC category was then calculated. To compare malignancy rates of inadequate specimens with those of adequate ones, we excluded FNAs that did not meet the adequacy criteria from that cohort and created a subgroup. Among a total of 1,925 FNAs reported according to TBSRTC, 1,446 thyroid FNAs from 1,359 patients were selected after excluding specimens consistent with lymphocytic thyroiditis in the proper clinical context or granulomatous thyroiditis, and other FNAs that did not meet adequacy criteria according to TBSRTC category were re-calculated only for adequate cases. The malignancy rates were presented with maximum and minimum values. A Pearson's Chi-square test or Fisher's exact test was performed to compare the maximum and minimum malignancy rates of inadequate specimens to those of adequate FNAs.

The diagnostic values of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for inadequate and adequate FNAs were calculated for resected nodules. Thyroid aspiration specimens interpreted as ND were excluded from these calculations1,3. Nodules with a benign FNA and final histology were considered true-negative cases. Surgically-confirmed malignant cases with FN/SFN, SM and malignant FNAs were regarded as true-positive results. AUS/FLUS nodules with malignant pathology on resection were also
considered true-positive cases. However, since the typical primary management process for AUS/FLUS lesions is not surgical resection\textsuperscript{13,15}, diagnostic indicators were re-assessed after excluding this category from analysis. These diagnostic values of inadequate samples were compared with those of adequate ones utilizing Pearson’s Chi-square test.

SPSS Software (Version 23, SPSS Inc., Chicago, IL, USA) was used for statistical analyses. This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center, and performed in accordance with relevant guidelines and regulations. The IRB waived the requirement for informed consent because all patient data was de-identified.

Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request and with permission of Samsung Medical Center.

References
1. Lee, Y. B. et al. Current status and diagnostic values of the Bethesda system for reporting thyroid cytopathology in a papillary thyroid carcinoma-prevalent area. \textit{Head & neck} \textbf{39}, 269–274 (2017).
2. Moon, H. J., Kim, E. K., Yoon, J. H. & Kwak, J. Y. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the Bethesda System. \textit{Radiology} \textbf{274}, 287–295 (2015).
3. Bongiovanni, M., Spitalte, A., Faquin, W. C., Mazzucchelli, L. & Baloch, Z. W. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. \textit{Acta cytoligica} \textbf{56}, 333–339 (2012).
4. Cibas, E. S. & Ali, S. Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. \textit{Thyroid: official journal of the American Thyroid Association} \textbf{27}, 1341–1346 (2017).
5. Cibas, E. S. & Ali, S. Z. The Bethesda System For Reporting Thyroid Cytopathology. \textit{American journal of clinical pathology} \textbf{132}, 658–665 (2009).
6. Vivero, M., Renshaw, A. A. & Krane, J. F. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. \textit{Cancer} \textbf{125}, 534–543 (2017).
7. Renshaw, A. A. Non-diagnostic rates for thyroid fine needle aspiration are negatively correlated with positive for malignancy rates. \textit{Acta cytoligica} \textbf{55}, 38–41 (2011).
8. Haider, A. S., Rakha, E. A., Dunkley, C. & Zaitoun, A. M. The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. \textit{Diagnostic cytopathology} \textbf{39}, 81–86 (2011).
9. Yoon, J. H., Lee, H. S., Kim, E. K., Moon, J. H. & Kwak, J. Y. Thyroid Nodules: Nondiagnostic Cytologic Results according to Thyroid Imaging Reporting and Data System before and after Application of the Bethesda System. \textit{Radiology} \textbf{276}, 579–587 (2015).
10. Pusztaszeri, M. et al. The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel. \textit{Acta cytoligica} \textbf{60}, 399–405 (2016).
11. Renshaw, A. A. Histologic follow-up of nondiagnostic thyroid fine needle aspirations: implications for adequacy criteria. \textit{Diagnostic cytopathology} \textbf{40}(Suppl 1), E13–15 (2012).
12. Hong, M. J., Na, D. G., Baek, J. H., Sung, J. Y. & Kim, J. H. Cytology-Ultrasonography Risk-Stratification Scoring System Based on Fine-Needle Aspiration Cytology and the Korean-Thyroid Imaging Reporting and Data System. \textit{Thyroid: official journal of the American Thyroid Association} \textbf{27}, 953–959 (2017).
13. Haugen, B. R. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. \textit{Thyroid: official journal of the American Thyroid Association} \textbf{26}, 1–133 (2016).
14. Brito, J. P. et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. \textit{The Journal of clinical endocrinology and metabolism} \textbf{99}, 1253–1263 (2014).
15. Shin, J. H. et al. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. \textit{Korean journal of radiology} \textbf{17}, 370–395 (2016).
16. Na, D. G. et al. Thyroid Imaging Reporting and Data System Risk Stratification of Thyroid Nodules: Categorization Based on Solidity and Echogenicity. \textit{Thyroid: official journal of the American Thyroid Association} \textbf{26}, 562–572 (2016).
17. Ha, E. J. et al. A Multicenter Prospective Validation Study for the Korean Thyroid Imaging Reporting and Data System in Patients with Thyroid Nodules. \textit{Korean journal of radiology} \textbf{17}, 811–821 (2016).
18. Khoon, M. L., Asa, S. L., Witterick, I. J. & Freeman, J. L. Thyroid calcification and its association with thyroid carcinoma. \textit{Head & neck} \textbf{24}, 651–655 (2002).
19. Wang, N., Xu, Y., Ge, C., Guo, R. & Guo, K. Association of sonographically detected calcification with thyroid carcinoma. \textit{Head & neck} \textbf{28}, 1077–1083 (2006).
20. DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. \textit{Pathology and Genetics of Tumours of Endocrine Organs, WHO Classification of Tumours.} 3rd edn, Vol. 8 (World Health Organization (IARC), 2004).
21. Ho, A. S. et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). \textit{Thyroid: official journal of the American Thyroid Association} \textbf{24}, 832–839 (2014).
22. Nikiforov, Y. E. et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. \textit{JAMA oncology} \textbf{2}, 1023–1029 (2016).

Author Contributions
Y.-B.L.: Data curation, formal analysis, and writing original draft. J.-Y.K. and H.C.: resources and methodology. S.Y.H., J.H.S., S.W.K., and J.H.C.: supervision and validation. S.E.L.: data curation. E.J.E.: formal analysis. T.H.K.: conceptualization, methodology, supervision, and writing - review and editing. Y.L.O.: conceptualization, methodology, supervision, and writing - review and editing. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-31955-9.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
